You are here: Industry Insights > Merck

News List

Merck and Pfizer provide update on avelumab in platinum-resistant/refractory ovarian cancer worldpharmanews
November 20, 2018
Four out of five patients with ovarian cancer are diagnosed at advanced stages. The disease often has no symptoms early on, when it is much more treatable.
Samsung BioLogics' crisis; Merck's Gardasil supply; China’s vaccine solution fiercepharma
November 18, 2018
South Korea’s securities regulators said Samsung BioLogics intentionally violated accounting rules and they suspended trading of its stock. Merck & Co. will provide $1.2 billion worth of Gardasil vaccines to China in 2020.
Merck starts rolling FDA submission for its Ebola vaccine, aiming to finish next year fiercepharma
November 16, 2018
Merck’s late-stage Ebola vaccine has already been deployed against recent outbreaks in the Democratic Republic of Congo. Now, after years of development, the company is ready to seek FDA approval.
Merck's Keytruda picks up first-in-class survival win in esophageal cancer fiercepharma
November 15, 2018
Merck’s Keytruda is looking to beat its immuno-oncology rivals into yet another market, and it just posted the data that could get the job done.
Merck's Keytruda picks up first-in-class survival win in esophageal cancer fiercepharma
November 15, 2018
Merck’s Keytruda is looking to beat its immuno-oncology rivals into yet another market, and it just posted the data that could get the job done.
Merck quadruples Gardasil supply in China contract but still might not meet full demand expressbpd
November 13, 2018
Facing buoyant demand in China for its HPV vaccines on the back of its Gardasil 9 launch, Merck & Co. has promised almost quadrupled supply in the coming years in a renewed contract with a local distributor.
AstraZeneca, Merck's Lynparza scores speedy review in blockbuster ovarian cancer market fiercepharma
November 13, 2018
Last month, AstraZeneca and Merck’s Lynparza posted big-time ovarian cancer data, and regulators are taking note.
Merck Q3 results: 5% revenue growth primarily driven by oncology pharmaceutical-technology
October 29, 2018
Revenue growth primarily driven by oncology.
Merck KGaA announces new results for bifunctional immunotherapy M7824 pharmatimes
October 25, 2018
Merck KGaA has announced new and updated results from expansion cohorts of two ongoing Phase I clinical trials (NCT02517398 and NCT02699515) for its immunotherapy M7824.
Merck joins Novartis, GlaxoSmithKline in grabbing a consumer executive to beef up digital fiercepharma
October 19, 2018
Merck joins Novartis, GlaxoSmithKline in grabbing a consumer executive to beef up digital

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page